Axios Future of Health Care

November 06, 2026
Somehow it's Friday. Here's an early look at how congressional Democrats will use their oversight powers over health policy and the administration in the next Congress.
⚡️ Join Axios Live in Washington, D.C., on Tuesday, Nov. 10, at 7:30am ET for conversations on health costs, access and bipartisan solutions with Rep. Morgan Griffith (R-Va.), Rep. Raul Ruiz (D-Calif.) and Georgetown University Center on Health Insurance Reforms founder Sabrina Corlette. RSVP here.
Today's newsletter is 909 words, a 3.5-minute read.
1 big thing: How Dems will apply oversight to health
Talk of subpoenas and warnings to "lawyer up" hint at the extent of the health care investigations and oversight hearings that Democrats are expected to launch once they take control of Congress.
Why it matters: Democrats have been building a paper trail for months to probe instances of political interference in vaccine policies, whether Health Secretary Robert F. Kennedy Jr. benefited financially from vaccine litigation and more.
- But the early efforts will more likely be directed at making a case for changes to federal Medicaid cuts, showcasing health affordability problems and examining whether federal health agencies are sufficiently funded and staffed.
- "You don't just do oversight to raise hell," said Tim Stretton, director of the Congressional Oversight Initiative at the Project On Government Oversight. "Trying to create some systematic change is arguably more important."
What we're hearing: The House Oversight, Energy and Commerce and Ways and Means committees will be focal points of early activity, along with the Senate health and Finance committees.
- Some law firms already are advising their corporate clients to cooperate with committee staffs and minimize their exposure to possible negative headlines from hearings.
- One prominent player will be the likely new House Oversight chair, Robert Garcia (D-Calif.) — the one who publicly warned Republicans to "lawyer up" on Tuesday after Democrats flipped control of the House.
- The former Long Beach mayor lost his mother, a frontline health worker, and stepfather to COVID and has publicly assailed Kennedy for undermining public health and preventing or delaying needed cures.
- Bernie Sanders' expected return to chair the Senate health committee will give the Vermont independent another chance to harness public outrage on drug prices and spar with Kennedy over his tenure as health secretary.
Zoom in: The power shift in Congress gives Democrats the ability to subpoena witnesses, demand records and hold officials and individuals in contempt if they don't comply.
- Hearings and investigations into problems with Affordable Care Act markets, drug pricing or hospital billing will likely be bipartisan in nature and feature ordinary citizens, to put a face on the problem.
- But Democrats will surely blame Trump administration policies and the conduct of officials for making Americans worse off. Garcia has said corruption within the administration is responsible for affordability woes.
- Along similar lines, likely Senate Finance Chair Ron Wyden (D-Ore.) has suggested that President Trump's drug pricing agreements amount to "sweetheart deals" with the pharmaceutical industry that won't help the vast majority of Americans.
What we're watching: Kennedy's tenure as secretary may constitute its own category of oversight and consume committees in both houses.
- Sanders is expected to bring up internal communications that the health committee's Democrats obtained from former CDC chief medical officer Debra Houry.
- Democrats say they show Kennedy changed vaccine recommendations without expert review and directed a federal vaccine advisory panel's actions to undermine access to vaccines.
- Another group of senators, including Wyden and Elizabeth Warren (D-Mass.), has questioned whether Kennedy personally benefited from a $50 million settlement around Merck's Gardasil human papillomavirus vaccine.
2. New screening rules for synthetic DNA
The administration yesterday rolled out new screening requirements for ordering sequences of synthetic DNA and equipment used to make it, replacing an honor system officials said may not stop malicious use of genetic materials.
Why it matters: AI's rapid advancement is changing the life sciences, but also expanding the field of players potentially capable of making a biological weapon.
Driving the news: The policy requires all recipients of federal funding to obtain synthetic nucleic acids and synthesis equipment from certified suppliers that verify customers and the sequences ordered.
- It calls on the National Institute of Standards and Technology, working with other departments and the private sector, to issue standards and screening protocols within 90 days.
- Customers that receive federal grants will have to buy all synthetic nucleic acids from certified suppliers within 250 days, and synthesis equipment within 340 days.
Context: AI is helping create longer and more complex genetic sequences — some of which aren't related to anything in nature. That could make screening more difficult.
- A recent RAND report outlined strategies including expanded screening of biological precursor substances at contract research organizations and cloud lab providers.
3. What we're reading
Four Kennedy appointees allowed to keep drug stocks (NYT)
Our take: These kinds of waivers exist throughout the government, but giving them to new Kennedy appointees to a federal preventive services task force raises the possibility of conflicts that could undermine panel recommendations.
Pharma's trade group spent heavily on search ads to sway public opinion (Stat)
Our take: It's another reminder of how much money is being thrown around to steer people's views of the industry.
Inside CVS' decision to break up a health care juggernaut (WSJ)
Our take: Unwinding one of health care's behemoths could shake up how patients get their medicines. Wall Street wasn't thrilled about prospects for a pure-play pharmacy company, either.
Thanks for reading Axios Future of Health Care, and to editor David Nather and copy editor Matt Piper. Please ask your friends and colleagues to sign up.
Sign up for Axios Future of Health Care





